Cytokinetics stock
CYTKNASDAQCytokinetics, Incorporated, HealthcareISIN US23282W6057
33Score 33 out of 100, Weak
Price and trend
32 / 100
Price history
−15% in one yearThe chart shows daily closes over 20 years, adjusted for stock splits and without dividends. Click into the chart to set a price alert at that price.
Below the 200-day line: the price is 20% below it.
Since October 2026 the 50-day line has been below the 200-day line; the trend has turned down.
Normal: the price is neither overheated nor sold off (RSI 39).
The price is 36% below its 52-week high. Largest decline in 20 years: 94% (February 2007 to October 2014).
Chart figures for advanced users
- SMA 50$64.47
- Average price of the last 50 trading days, shows the short-term trend.
- SMA 200$69.83
- Average price of the last 200 trading days, shows the long-term trend.
- RSI (14)39
- Relative strength over the last 14 days on a scale from 0 to 100. Above 70 the price counts as overheated, below 30 as sharply fallen.
- MACDbelow the signal line
- Compares a fast and a slow price average. Above its signal line momentum is rising, below it momentum is fading.
- Support$53.69
- The lowest closing price of the last twelve months.
- Resistance$87.26
- The highest closing price of the last twelve months.
Snapshot
Computed from the data by fixed rules, no AI
- Cytokinetics, Incorporated belongs to the Biotechnology industry (United States) and, with a market value of $7.82B, is number 49 of 289 companies in its industry on MEQIRI.
- In fiscal 2025 it reported revenue of $88.04M (up 376.6% year on year) and a loss of $784.96M.
- For fiscal 2026, analysts expect on average revenue of $159.36M (up 81%) and adjusted earnings per share of −$5.94.
Show more
- MEQIRI Score 33 out of 100 (Weak): rank 641 of 702 in Healthcare, median 53.
In plain words
The numbers on this page in plain words, written by an AI
Strengths
None of our strength checks applies.
Weaknesses
- DilutionShare count up 86% since 2020.Capital allocation 18
- Loss-makingLoss of $777.89M over the last 12 months.Fundamentals 17
- Negative free cash flowFree cash flow −$588.58M over the last 12 months.Fundamentals 17
The score is held back by capital allocation and fundamentals.
Daily figure as of 13 Nov 2026
How the score is calculatedScore overview
Score since yesterday from 34 to 33.
Fundamental quality fluctuates.
Score history
The full history of up to 20 years comes with MEQIRI Pro.
See plansValuation
Valuation signal
not measuredNo fair value can be calculated for this stock, so the signal follows the valuation grade.
Valuation metrics
No fair value can be calculated for this stock from the available figures.
Calculate with your own assumptionsCompany performance
This shows several years of history with an automatic assessment.
Revenue
In fiscal 2025, revenue rose 377% on the prior year. Revenue has grown strongly since 2006, at around 19% per year.
Margins
- Gross margin
- Operating margin
- Net margin
In fiscal 2025: gross 88%, operating −695%, net −892%. Last 12 months: net −100%.
Debt & balance sheet
latest quarterDebt is elevated. Keep an eye on the interest burden and refinancing.
Earnings
- Next earnings
- 23 Feb 2027in 102 days
- Last reported
- 4 Nov 2026EPS reported −$1.37 (expected −$1.43)above expectations
Analyst estimates
Earnings estimates have barely changed since 15 Oct 2026.
- Earnings per share
- −$5.94+1.5%
- Revenue
- $159.36M+5.0%
- Earnings per share
- −$4.38+1.6%
- Revenue
- $437.16M+3.3%
MEQIRI has stored the estimates since 15 Oct 2026. Until 30 days are available, the card shows the change since that day. Mean estimate according to Financial Modeling Prep. No price target and no recommendation.
Company outlook raised
Share price after the results: −2.7%The MYQORZO launch is running ahead of expectations; planned R&D and SG&A spending rose to $860 million to $890 million (previously $830 million to $870 million) to prepare a further launch.
“We are updating full year 2026 GAAP combined R&D and SG&A expense to a range of $860 million to $890 million from the previous range of $830 million to $870 million.”The outlook is not part of the score and not a recommendation to buy or sell.
From the earnings call on 6 Aug 2026 (fiscal Q2 2026), read by AI.
Insiders
Open-market purchases and sales by executives, board members and major holders
No open-market purchases in the last 6 months. 7 insiders sold, $25.36M in total.
Sales say less than purchases: many insiders sell on a fixed plan, for taxes or to diversify.
- Parshall B LynneSale
9 Nov 2026, Board
- Shares
- 5,000
- Price
- $54.73
- Value
- $273,635
- Malik Fady IbrahamSale
3 Nov 2026, EVP Research & Development
- Shares
- 3,500
- Price
- $62.93
- Value
- $220,255
- Blum Robert ISale
2 Nov 2026, President & CEO
- Shares
- 7,500
- Price
- $62.81
- Value
- $471,075
Show 34 more
- Malik Fady IbrahamSale
20 Oct 2026, EVP Research & Development
- Shares
- 3,500
- Price
- $64.01
- Value
- $224,035
- Blum Robert ISale
12 Oct 2026, President & CEO
- Shares
- 7,500
- Price
- $62.88
- Value
- $471,600
- Malik Fady IbrahamSale
6 Oct 2026, EVP Research & Development
- Shares
- 3,500
- Price
- $61.38
- Value
- $214,830
- Blum Robert ISale
28 Sept 2026, President & CEO
- Shares
- 7,500
- Price
- $65.46
- Value
- $490,950
- Malik Fady IbrahamSale
22 Sept 2026, EVP Research & Development
- Shares
- 3,500
- Price
- $68.29
- Value
- $239,015
- Landry Robert ESale
15 Sept 2026, Board
- Shares
- 1,000
- Price
- $72.13
- Value
- $72,130
- Blum Robert ISale
15 Sept 2026, President & CEO
- Shares
- 97,926
- Price
- $69.33
- Value
- $6.79M
- Blum Robert ISale
14 Sept 2026, President & CEO
- Shares
- 7,500
- Price
- $73.44
- Value
- $550,800
- Landry Robert ESale
11 Sept 2026, Board
- Shares
- 1,000
- Price
- $74.66
- Value
- $74,660
- Malik Fady IbrahamSale
8 Sept 2026, EVP Research & Development
- Shares
- 3,500
- Price
- $75.46
- Value
- $264,110
- Parshall B LynneSale
1 Sept 2026, Board
- Shares
- 5,000
- Price
- $71.48
- Value
- $357,400
- Callos AndrewSale
31 Aug 2026, EVP, Chief Commercial Officer
- Shares
- 10,000
- Price
- $70.24
- Value
- $702,400
- Blum Robert ISale
31 Aug 2026, President & CEO
- Shares
- 7,500
- Price
- $70.24
- Value
- $526,800
- Malik Fady IbrahamSale
18 Aug 2026, EVP Research & Development
- Shares
- 3,500
- Price
- $75.82
- Value
- $265,370
- Blum Robert ISale
10 Aug 2026, President & CEO
- Shares
- 7,500
- Price
- $76.76
- Value
- $575,700
- Callos AndrewSale
30 Jul 2026, EVP, Chief Commercial Officer
- Shares
- 14,000
- Price
- $79.88
- Value
- $1.12M
- Blum Robert ISale
27 Jul 2026, President & CEO
- Shares
- 7,500
- Price
- $80.87
- Value
- $606,525
- Malik Fady IbrahamSale
21 Jul 2026, EVP Research & Development
- Shares
- 3,500
- Price
- $80.59
- Value
- $282,065
- Blum Robert ISale
13 Jul 2026, President & CEO
- Shares
- 7,490
- Price
- $82.02
- Value
- $614,330
- Malik Fady IbrahamSale
7 Jul 2026, EVP Research & Development
- Shares
- 3,500
- Price
- $86.62
- Value
- $303,170
- Blum Robert ISale
1 Jul 2026, President & CEO
- Shares
- 7,500
- Price
- $84.92
- Value
- $636,900
- Callos AndrewSale
1 Jul 2026, EVP, Chief Commercial Officer
- Shares
- 15,000
- Price
- $85.80
- Value
- $1.29M
- Lee SungSale
1 Jul 2026, EVP, Chief Financial Officer
- Shares
- 1,112
- Price
- $87.79
- Value
- $97,622
- Lee SungSale
29 Jun 2026, EVP, Chief Financial Officer
- Shares
- 3,134
- Price
- $85.00
- Value
- $266,390
- Lee SungSale
24 Jun 2026, EVP, Chief Financial Officer
- Shares
- 38,730
- Price
- $82.30
- Value
- $3.19M
- Malik Fady IbrahamSale
23 Jun 2026, EVP Research & Development
- Shares
- 3,500
- Price
- $79.51
- Value
- $278,285
- Blum Robert ISale
15 Jun 2026, President & CEO
- Shares
- 7,500
- Price
- $70.46
- Value
- $528,450
- Malik Fady IbrahamSale
9 Jun 2026, EVP Research & Development
- Shares
- 3,500
- Price
- $67.98
- Value
- $237,930
- Kaye Edward M. MDSale
1 Jun 2026, Board
- Shares
- 2,933
- Price
- $76.09
- Value
- $223,172
- Callos AndrewSale
1 Jun 2026, EVP, Chief Commercial Officer
- Shares
- 15,000
- Price
- $74.08
- Value
- $1.11M
- Parshall B LynneSale
1 Jun 2026, Board
- Shares
- 5,000
- Price
- $74.08
- Value
- $370,400
- Blum Robert ISale
27 May 2026, President & CEO
- Shares
- 7,500
- Price
- $77.21
- Value
- $579,075
- Malik Fady IbrahamSale
19 May 2026, EVP Research & Development
- Shares
- 3,500
- Price
- $75.69
- Value
- $264,915
- Blum Robert ISale
14 May 2026, President & CEO
- Shares
- 7,500
- Price
- $77.92
- Value
- $584,400
Partial trades from one filing are shown in one row, with the average price.
Source: Form 4 filings with the US Securities and Exchange Commission. Grants, option exercises, gifts and tax withholdings are hidden. Not a recommendation to buy.
What happened at Cytokinetics
The key events of the last six months from our own data. A click takes you to the matching card.
Sector comparison
702 rated companies in Healthcare
- This company
- 33
- Sector median
- 53
Categories against the sector medianMedian of 702 companies
The median is the middle value: half of the companies in the sector lie above it, half below. Categories with too few comparable companies are left out.
Competitors in Biotechnology
The next larger and next smaller companies by market value
- Asymchem Laboratories (Tianjin)002821.SZ $8.29B64
- RemeGen688331.SS $8.26B44
- ALK-AbellóALK-B.CO $8.18B74
- AbivaxABVX.PA $8B35
- 10x GenomicsTXG $7.73B43
- Rhythm PharmaceuticalsRYTM $7.62B41
- Axsome TherapeuticsAXSM $7.59B31
- Twist BioscienceTWST $7.52B46
ETFs that hold Cytokinetics
Held by 15 ETFs on Xetra. Shown per index: the ETF with the largest weight.
| ETF | Weight | Cost | Fund size |
|---|---|---|---|
| iShares Nasdaq US Biotechnology UCITS ETF2B70 | 0.51% | 0.35% | €1.25B |
| iShares Ageing Population UCITS ETF2B77 | 0.38% | 0.40% | €813.42M |
| State Street SPDR Russell 2000 U.S. Small Cap UCITS ETF (Acc)ZPRR | 0.25% | 0.30% | €4.28B |
Show 5 more
| Xtrackers Russell 2000 UCITS ETF 1CXRS2 | 0.25% | 0.30% | €2.22B |
| State Street SPDR S&P 400 U.S. Mid Cap UCITS ETF (Acc)SPY4 | 0.23% | 0.30% | €5.36B |
| L&G Russell 2000 US Small Cap Quality UCITS ETFETLZ | 0.18% | 0.30% | €185.82M |
| iShares MSCI USA Small Cap CTB Enhanced ESG UCITS ETFSXRG | 0.15% | 0.43% | €2.5B |
| iShares MSCI World Small Cap CTB Enhanced ESG UCITS ETFCBUG | 0.12% | 0.10% | €395.74M |
Holdings as reported by the funds via FMP, excluding swap ETFs (their holdings are only collateral).
Data status and sources
- Score
- Daily value of 13 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Weak, published since 7 Nov 2026 (in the score history since 31 Aug 2017)
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.